

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

RIGEL PHARMACEUTICALS, INC.,

Petitioner,

v.

SERVIER PHARMACEUTICALS LLC

Patent Owner.

---

Case IPR2022-01423  
U.S. Patent No. 10,610,125

---

**DECLARATION OF DR. LESLIE OLEKSOWICZ  
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW  
U.S. PATENT NO. 10,610,125**

**TABLE OF CONTENTS**

LIST OF EXHIBITS REFERENCED IN DECLARATION ..... iii

I. INTRODUCTION.....1

II. BACKGROUND AND QUALIFICATIONS .....2

III. MATERIALS CONSIDERED .....5

IV. MY UNDERSTANDING OF CERTAIN LEGAL STANDARDS .....6

    A. Ordinary Skill in the Art.....6

    B. Claim Construction.....7

    C. Prior Art and Priority .....8

V. BACKGROUND.....10

    A. Overview of Technology .....10

    B. The '125 Patent.....17

    C. Technical Background and Prior Art.....24

        1. Parsons .....24

        2. Bleeker.....25

        3. Kang.....26

        4. Yan.....27

        5. Zhao .....28

        6. Mardis.....29

        7. Vogelstein.....31

        8. Dang 2009.....33

VI. A PERSON OF ORDINARY SKILL IN THE RELEVANT FIELD IN THE  
    RELEVANT TIMEFRAME .....36

VII. CLAIM CONSTRUCTION .....37

VIII. SUMMARY OF MY OPINIONS .....37

IX. THE CHALLENGED CLAIMS ARE NOT ENTITLED TO ANY PRIORITY  
    DATE EARLIER THAN JULY 11, 2013 .....38

Declaration of Dr. Leslie Oleksowicz  
U.S. Patent No. 10,610,125

A. The state of the art as of March 2010.....38

B. The scope of the Challenged Claims is broad.....42

C. The disclosure of the 2010 Application does not provide sufficient information to demonstrate possession of methods for treating IDH1-mutant AML .....44

**LIST OF EXHIBITS REFERENCED IN DECLARATION**

| <b>Exhibit</b> | <b>Description</b>   |
|----------------|--|
| 1001           | U.S. Patent No. 10,610,125 (“125 Patent”)  |
| 1002           | Excerpted Prosecution History of U.S. Patent No. 10,610,125  |
| 1005           | Declaration of Doctor Leslie Oleksowicz (“Oleksowicz Dec.”)  |
| 1006           | Curriculum Vitae of Doctor Leslie Oleksowicz   |
| 1007           | Mardis et al., <i>Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome</i> , 361 N. ENGL. J. MED. 1058 (2009). (“Mardis”)  |
| 1008           | Vogelstein et al., U.S. Pat. App. Pub. No. 2011/0229479 (“Vogelstein”)   |
| 1009           | Dang et al., Int’l Pat. App. Pub. No. 2010/105243 (“Dang ’243” or “2010 Application”)  |
| 1010           | Popovici-Muller et al., Int’l Pat. App. Pub. No. 2012/009678 (“PM ’678”)   |
| 1011           | Popovici-Muller et al., <i>Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo</i> , 3 ACS MED. CHEM. LETT. 850 (2012). (“PM 2012”)                        |
| 1012           | Zhao et al. <i>Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1<math>\alpha</math></i> , 324 SCIENCE 261 (2009).                                 |
| 1014           | Golub et al., <i>Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics</i> , 9 FRONT. ONCOL. 417 (2019). (“Golub”)  |
| 1015           | Parsons et al., <i>An Integrated Genomic Analysis of Human Glioblastoma Multiform</i> , SCIENCEEXPRESS (2008). (“Parsons”)   |
| 1016           | Yan et al., <i>IDH1 and IDH2 Mutations in Gliomas</i> , 360 N. ENGL. J. MED. 765 (2009). (“Yan”)   |
| 1017           | Bleeker et al., <i>IDH1 Mutations at Residue p.R132 (IDH1<sup>R132</sup>) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors</i> , 30 HUMAN MUTATION 7 (2009). (“Bleeker”) |

| <b>Exhibit</b> | <b>Description</b>   |
|----------------|--|
| 1019           | Kang et al., <i>Mutational Analysis of IDH1 Codon 132 in Glioblastomas and Other Common Cancers</i> , 125 INT. J. CANCER 353 (2009). (“Kang”)  |
| 1022           | Gross et al., <i>Cancer-associated Metabolite 2-hydroxyglutarate Accumulates in Acute Myelogenous Leukemia With Isocitrate Dehydrogenase 1 and 2 Mutations</i> , 207 J. EXP. MED. 339 (2010). (“Gross”)  |
| 1024           | Dang et al., <i>Cancer-associated IDH1 Mutations Produce 2-hydroxyglutarate</i> , 462 NATURE 739 (2009). (“Dang 2009”)   |
| 1052           | Frezza et al. <i>IDH1 Mutations in Gliomas: When an Enzyme Loses its Grip</i> , 17 Cancer Cell 7-9 (2010). (“Frezza”)  |
| 1053           | FDA, GLEEVEC® PRESCRIBING INFORMATION (2022)<br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf</a> .  |
| 1054           | <i>Biomarkers, KIT Mutation</i> , MY CANCER GENOME,<br><a href="https://www.mycancergenome.org/content/alteration/kit-mutation/#:~:text=KIT%20Mutation%20is%20present%20in,the%20greatest%20prevalence%20%5B4%5D">https://www.mycancergenome.org/content/alteration/kit-mutation/#:~:text=KIT%20Mutation%20is%20present%20in,the%20greatest%20prevalence%20%5B4%5D</a> . (last visited Aug. 14, 2022). |
| 1055           | <i>BRAFTOVI® Prescribing Information</i> , PFIZER,<br><a href="https://labeling.pfizer.com/ShowLabeling.aspx?id=12990">https://labeling.pfizer.com/ShowLabeling.aspx?id=12990</a> (last visited Aug. 14, 2022).  |
| 1056           | Turski et al., <i>Genomically Driven Tumors and Actionability Across Histologies: BRAF-Mutant Cancers as a Paradigm</i> , 15 MOL. CANCER. THER. 533-47 (2016). (“Turski”)  |
| 1057           | Kumar et al. <i>Genetic Abnormalities and Challenges in the Treatment of AML</i> , 2 GENES & CANCER 95-107 (2011). (“Kumar”)   |
| 1058           | Popovici-Muller et al., <i>Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</i> , 9 ACS MED. CHEM. LETT. 300-5 (2018). (“PM 2018”)  |

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.